Tag: NASDAQ: APTO

Business

Aptose Biosciences Inc. (NASDAQ: APTO) Provides Updates on Luxeptinib Study in AML Treatment; Shares Plunge 32%

Aptose Biosciences Inc. (NASDAQ: APTO) dropped 32.01% after the releases of its corporate update highlights on June 11, 2021, focusing on the luxeptinib clinical status. Luxeptinib is the company’s first-in-class oral FLT3 and BTK kinases inhibitor under evaluation for refractory or relapsed acute myeloid leukemia (AML) and r/r B cell […]